Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel in Metastatic Breast Cancer (Tiffany)
NCT01416558Phase 2Terminated
- Sponsor
- GBG Forschungs
- Start
- Jul 2011
- Primary completion
- Oct 2012
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in breast cancer, sponsored by GBG Forschungs. Primary endpoint: Overall Response Rate at 3 years. Started Jul 2011; status: terminated.
02
Drugs
nab-paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01416558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01416558.